체외 폐 모델 시장 : 성장, 향후 전망, 경쟁 분석(2024-2032년)

The in vitro lung model market is a specialized segment within the broader field of medical research and biotechnology. This market focuses on the development, production, and utilization of in vitro (outside the living organism) models that simulate the structure and function of human lungs. These models are crucial for various applications in respiratory research, drug discovery, and toxicology testing. The in vitro lung model market is estimated to grow at a CAGR of 17.2% from 2024 to 2032. In vitro lung models are laboratory models that mimic the biological characteristics of human lungs. They are developed using various techniques, including cell cultures, organ-on-a-chip technology, and 3D bioprinting. These models aim to replicate the lung's cellular environment, structural features, and physiological responses, providing a more accurate and ethical alternative to traditional animal testing.

Driver: Growing Need for Advanced Respiratory Disease Research

The in vitro lung model market is primarily driven by the growing need for advanced respiratory disease research. This demand is fueled by the increasing prevalence of respiratory diseases globally, including chronic obstructive pulmonary disease (COPD), asthma, and lung cancer. According to the World Health Organization, COPD alone is the third leading cause of death worldwide, and asthma affects millions of people globally. This rising burden of respiratory diseases necessitates more effective research tools for understanding disease mechanisms, developing new treatments, and improving patient outcomes. In vitro lung models offer a promising solution by providing a more accurate and ethical alternative to animal testing, enabling detailed study of lung diseases at the cellular and molecular level. The COVID-19 pandemic further highlighted the importance of lung research, as scientists worldwide turned to in vitro lung models to study the virus's effects on lung tissue and test potential treatments. This has underscored the essential role of these models in respiratory disease research and drug development, driving significant growth in the market.

Opportunity: Technological Advancements in Lung Models

The in vitro lung model market presents significant opportunities with technological advancements in lung model development. Innovations such as 3D bioprinting and organ-on-a-chip technology are revolutionizing the field, enabling the creation of more complex and physiologically relevant lung models. These advancements are not only enhancing the accuracy of drug efficacy and toxicity testing but also opening new avenues in personalized medicine. For instance, lung models can now be developed using cells from specific patients, allowing for more personalized drug response testing and the potential development of customized treatments. This technological evolution aligns with the growing trend towards personalized healthcare and precision medicine, making it a lucrative opportunity for market growth. As these technologies continue to mature and become more accessible, they are expected to significantly expand the applications and capabilities of in vitro lung models.

Restraint: High Costs and Technical Complexities

Despite the potential of in vitro lung models, the market faces significant restraints in terms of high costs and technical complexities. Developing and maintaining sophisticated lung models, especially those using cutting-edge technologies like organ-on-a-chip, requires substantial financial investment. The high costs associated with these technologies can be a barrier for academic and smaller research institutions, limiting the widespread adoption of advanced lung models. Additionally, the technical complexities involved in creating and using these models require specialized expertise and resources. This not only adds to the cost but also limits the availability of skilled professionals who can effectively utilize these models for research purposes. As such, the high cost and technical complexity of advanced in vitro lung models remain major challenges in the market, potentially hindering broader adoption and innovation.

Challenge: Replicating the Complexity of Human Lungs

One of the biggest challenges in the in vitro lung model market is replicating the intricate complexity of human lungs. The lung is a highly complex organ with a unique structure and diverse cell types, making it difficult to accurately mimic in a laboratory setting. While recent technological advancements have made significant strides in this area, there is still a gap between the current capabilities of in vitro models and the complexity of real human lungs. This challenge is critical because the efficacy of lung models in research and drug development heavily depends on how accurately they replicate human lung physiology and pathology. Overcoming this challenge requires ongoing research and innovation to develop more sophisticated models that can closely mimic the intricate architecture, cellular diversity, and dynamic physiological responses of human lungs. Addressing this issue is essential for the continued advancement and utility of in vitro lung models in respiratory research.

Market segmentation by type

In the in vitro lung model market, segmentation by type includes 2D and 3D Models, each with distinct growth patterns and revenue contributions. The 3D Model segment currently holds the highest revenue within this market. This prominence is due to the advanced capabilities of 3D models in closely replicating the structural and functional aspects of human lungs, making them highly valuable for complex studies in drug discovery and disease modeling. Their ability to provide a more physiologically relevant environment compared to traditional 2D cultures has led to their widespread adoption in advanced research settings. The revenue dominance of 3D models is further reinforced by their increasing use in studying intricate lung diseases and testing the efficacy of respiratory drugs. However, the segment expected to exhibit the highest Compound Annual Growth Rate (CAGR) is the 2D Model segment. While 3D models offer advanced features, 2D models are still widely used due to their simplicity, lower cost, and ease of use. The demand for 2D models is expected to grow, particularly in basic research and routine testing, where the complexity and cost of 3D models may not be necessary.

Market Segmentation by Application

Regarding market segmentation by application, the in vitro lung model market includes Drug Discovery & Toxicology Studies, Physiological Research, 3D Model Development, among others. The Drug Discovery & Toxicology Studies segment has generated the highest revenue, attributed to the critical role these models play in the pharmaceutical industry. They are extensively used for screening potential drug candidates and assessing their toxicity, significantly reducing the time and cost associated with drug development. The increasing investment in pharmaceutical R&D, along with the rising demand for new respiratory drugs, especially post the COVID-19 pandemic, has fueled the growth of this segment. In terms of the highest CAGR, the Physiological Research segment is projected to grow rapidly. This growth is driven by the escalating need to understand complex lung diseases at a fundamental level, including studying the pathophysiology of conditions like COPD, asthma, and lung cancers. As the scientific community's understanding of these diseases deepens, the demand for in vitro lung models in physiological research is expected to increase significantly, driven by the need for more sophisticated and accurate models to mimic human lung physiology.

Regional Insights

The in vitro lung model market's geographic segmentation highlights varied growth and revenue patterns across different regions. In 2023, North America emerged as the region with the highest revenue in this market. This leadership can be attributed to the region's advanced healthcare research infrastructure, significant investments in R&D, and the presence of key pharmaceutical and biotech companies engaged in lung-related research. The high prevalence of respiratory diseases and the strong focus on developing innovative treatment solutions in North America further contributed to its dominant revenue position. Looking towards 2024 to 2032, the Asia-Pacific region is expected to experience the highest Compound Annual Growth Rate (CAGR). This growth projection is driven by increasing investments in healthcare research, rising incidence of respiratory diseases, and growing awareness of advanced research methodologies in countries like China and India. Additionally, the expanding healthcare infrastructure and increasing government support for biotechnology research in these regions are likely to fuel the growth of the in vitro lung model market.

Competitive Trends

In terms of competitive trends, the market is characterized by a mix of established players and emerging entrants, each employing distinct strategies to strengthen their market positions. In 2023, companies such as Epithelix, MATTEK, Lonza, Emulate, AlveoliX AG, Nortis, CN Bio Innovations Ltd., MIMETAS, InSphero, ATTC Global were among the top players, leveraging their extensive research capabilities and robust product portfolios to dominate the market. These companies focused on strategic collaborations, mergers, and acquisitions to broaden their technological capabilities and enhance their market reach. For the forecast period of 2024 to 2032, these key players are expected to continue emphasizing innovation, particularly in areas like 3D bioprinting and organ-on-a-chip technologies. Investment in these advanced technologies is anticipated to be a crucial strategy for maintaining a competitive edge. Furthermore, these companies are likely to expand their presence in emerging markets, adapting to the evolving research needs and regulatory landscapes. The entry of new players specializing in innovative lung model technologies is expected to intensify competition in the market, thereby driving continuous advancements in the field of in vitro lung models.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of In Vitro Lung Model market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the In Vitro Lung Model market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Type

2D Model

3D Model

Application

• Drug Discovery & Toxicology Studies
• Physiological Research

3D Model Development

• Others

End-Use

• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of In Vitro Lung Model market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the In Vitro Lung Model market?

Which is the largest regional market for In Vitro Lung Model market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving In Vitro Lung Model market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the In Vitro Lung Model market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global In Vitro Lung Model Market
• 2.2. Global In Vitro Lung Model Market, By Type, 2023 (US$ Million)
• 2.3. Global In Vitro Lung Model Market, By Application, 2023 (US$ Million)
• 2.4. Global In Vitro Lung Model Market, By End-Use, 2023 (US$ Million)
• 2.5. Global In Vitro Lung Model Market, By Geography, 2023 (US$ Million)
• 2.6. Attractive Investment Proposition by Geography, 2023

3. In Vitro Lung Model Market: Competitive Analysis

• 3.1. Market Positioning of Key In Vitro Lung Model Market Vendors
• 3.2. Strategies Adopted by In Vitro Lung Model Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2023 Versus 2032

4. In Vitro Lung Model Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global In Vitro Lung Model Market Value, 2022 - 2032, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis
• 4.6. Porter's Five Force Model
  • 4.6.1. Supplier Power
  • 4.6.2. Buyer Power
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Competitive Rivalry
• 4.7. PESTEL Analysis
  • 4.7.1. Political Landscape
  • 4.7.2. Economic Landscape
  • 4.7.3. Technology Landscape
  • 4.7.4. Legal Landscape
  • 4.7.5. Social Landscape

5. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2023 Versus 2032
• 5.3. Market Segmentation
  • 5.3.1. 2D Model
  • 5.3.2. 3D Model

6. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2023 Versus 2032
• 6.3. Market Segmentation
  • 6.3.1. Drug Discovery & Toxicology Studies
  • 6.3.2. Physiological Research
  • 6.3.3. 3D Model Development
  • 6.3.4. Others

7. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2023 Versus 2032
• 7.3. Market Segmentation
  • 7.3.1. Academic Research Institutes
  • 7.3.2. Pharmaceutical & Biotechnology Companies
  • 7.3.3. Others

8. North America In Vitro Lung Model Market, 2022-2032, USD (Million)

• 8.1. Market Overview
• 8.2. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
• 8.3. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
• 8.4. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
• 8.5.In Vitro Lung Model Market: By Region, 2022-2032, USD (Million)
  • 8.5.1.North America
    • 8.5.1.1. U.S.
      • 8.5.1.1.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.1.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 8.5.1.1.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 8.5.1.2. Canada
      • 8.5.1.2.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.2.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 8.5.1.2.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 8.5.1.3. Rest of North America
      • 8.5.1.3.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.3.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 8.5.1.3.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)

9. UK and European Union In Vitro Lung Model Market, 2022-2032, USD (Million)

• 9.1. Market Overview
• 9.2. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
• 9.3. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
• 9.4. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
• 9.5.In Vitro Lung Model Market: By Region, 2022-2032, USD (Million)
  • 9.5.1.UK and European Union
    • 9.5.1.1. UK
      • 9.5.1.1.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.1.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 9.5.1.1.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 9.5.1.2. Germany
      • 9.5.1.2.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.2.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 9.5.1.2.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 9.5.1.3. Spain
      • 9.5.1.3.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.3.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 9.5.1.3.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 9.5.1.4. Italy
      • 9.5.1.4.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.4.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 9.5.1.4.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 9.5.1.5. France
      • 9.5.1.5.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.5.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 9.5.1.5.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 9.5.1.6. Rest of Europe
      • 9.5.1.6.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.6.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 9.5.1.6.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)

10. Asia Pacific In Vitro Lung Model Market, 2022-2032, USD (Million)

• 10.1. Market Overview
• 10.2. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
• 10.3. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
• 10.4. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
• 10.5.In Vitro Lung Model Market: By Region, 2022-2032, USD (Million)
  • 10.5.1.Asia Pacific
    • 10.5.1.1. China
      • 10.5.1.1.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.1.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 10.5.1.1.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 10.5.1.2. Japan
      • 10.5.1.2.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.2.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 10.5.1.2.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 10.5.1.3. India
      • 10.5.1.3.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.3.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 10.5.1.3.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 10.5.1.4. Australia
      • 10.5.1.4.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.4.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 10.5.1.4.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 10.5.1.5. South Korea
      • 10.5.1.5.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.5.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 10.5.1.5.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 10.5.1.6. Rest of Asia Pacific
      • 10.5.1.6.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.6.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 10.5.1.6.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)

11. Latin America In Vitro Lung Model Market, 2022-2032, USD (Million)

• 11.1. Market Overview
• 11.2. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
• 11.3. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
• 11.4. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
• 11.5.In Vitro Lung Model Market: By Region, 2022-2032, USD (Million)
  • 11.5.1.Latin America
    • 11.5.1.1. Brazil
      • 11.5.1.1.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.1.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 11.5.1.1.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 11.5.1.2. Mexico
      • 11.5.1.2.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.2.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 11.5.1.2.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 11.5.1.3. Rest of Latin America
      • 11.5.1.3.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.3.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 11.5.1.3.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)

12. Middle East and Africa In Vitro Lung Model Market, 2022-2032, USD (Million)

• 12.1. Market Overview
• 12.2. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
• 12.3. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
• 12.4. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
• 12.5.In Vitro Lung Model Market: By Region, 2022-2032, USD (Million)
  • 12.5.1.Middle East and Africa
    • 12.5.1.1. GCC
      • 12.5.1.1.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.1.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 12.5.1.1.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 12.5.1.2. Africa
      • 12.5.1.2.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.2.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 12.5.1.2.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)
    • 12.5.1.3. Rest of Middle East and Africa
      • 12.5.1.3.1. In Vitro Lung Model Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.3.2. In Vitro Lung Model Market: By Application, 2022-2032, USD (Million)
      • 12.5.1.3.3. In Vitro Lung Model Market: By End-Use, 2022-2032, USD (Million)

13. Company Profile

• 13.1. Epithelix
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Portfolio
  • 13.1.4. Strategic Initiatives
• 13.2. MATTEK
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Portfolio
  • 13.2.4. Strategic Initiatives
• 13.3. Lonza
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Portfolio
  • 13.3.4. Strategic Initiatives
• 13.4. Emulate
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Portfolio
  • 13.4.4. Strategic Initiatives
• 13.5. AlveoliX AG
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Portfolio
  • 13.5.4. Strategic Initiatives
• 13.6. Nortis
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Portfolio
  • 13.6.4. Strategic Initiatives
• 13.7. CN Bio Innovations Ltd.
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Portfolio
  • 13.7.4. Strategic Initiatives
• 13.8. MIMETAS
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Portfolio
  • 13.8.4. Strategic Initiatives
• 13.9. InSphero
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Portfolio
  • 13.9.4. Strategic Initiatives
• 13.10. ATTC Global
  • 13.10.1. Company Overview
  • 13.10.2. Financial Performance
  • 13.10.3. Product Portfolio
  • 13.10.4. Strategic Initiatives
• 13.11. Other Notable Players
  • 13.11.1. Company Overview
  • 13.11.2. Financial Performance
  • 13.11.3. Product Portfolio
  • 13.11.4. Strategic Initiatives